Ocugen, Inc. 2022 Form 10-K Summary
Business context and reporting period
Ocugen, Inc. is a biotechnology company developing gene therapies, cell therapies, biologics, and vaccines. The filing covers the fiscal year ended December 31, 2022, with comparisons to 2021. The company operates as one segment and has not generated product revenue or commercialized an approved product.
- Modifier gene therapy: OCU400 for inherited retinal diseases; OCU410 for dry age-related macular degeneration; and OCU410ST for Stargardt disease.
- Regenerative medicine: NeoCart for repair of knee cartilage injuries.
- Vaccines: COVAXIN for the United States, Canada, and Mexico, and an inhaled mucosal vaccine platform comprising OCU500, OCU510, and OCU520.
- Novel biologic: OCU200 for diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration.
Financial performance and key metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $49.8 million | $35.1 million | +$14.6 million |
| General and administrative expense | $35.1 million | $22.9 million | +$12.2 million |
| Total operating expenses | $84.9 million | $58.0 million | +$26.8 million |
| Loss from operations | $(84.9) million | $(58.0) million | $(26.8) million |
| Other income, net | $3.5 million | $(0.4) million | +$3.9 million |
| Net loss | $(81.4) million | $(58.4) million | $(23.0) million |
| Net loss per share | $(0.38) | $(0.30) | $(0.08) |
| Net cash used in operating activities | $(60.1) million | $(47.9) million | $(12.1) million |
| Cash, cash equivalents, and marketable securities | $90.9 million | $95.0 million in cash and equivalents | Lower total liquidity |
Gross and operating margins are not meaningful because the company reported no revenue. The accumulated deficit was $213.0 million at December 31, 2022. Stock-based compensation expense increased to $10.5 million from $7.0 million.
Liquidity, capital resources, debt, and commitments
- Cash and cash equivalents were $77.6 million; marketable securities were $13.4 million, consisting of U.S. government agency securities, treasuries, and commercial paper.
- Operating cash burn increased to $60.1 million from $47.9 million.
- Financing activities provided $59.5 million, primarily from a February 2022 public offering and sales under an at-the-market program. Ocugen issued 16.0 million shares in the public offering and received net proceeds of $49.8 million.
- Property and equipment increased to $6.1 million from $1.2 million, reflecting investment in facilities and equipment, including the planned NeoCart manufacturing facility.
- Outstanding debt included $2.0 million of EB-5 principal borrowings, with a $2.3 million carrying value including accrued interest and net debt issuance costs. The debt bears fixed interest at 4.0% and is secured by substantially all assets other than intellectual property.
- Future base operating lease payments totaled approximately $5.0 million, including approximately $0.8 million due within 12 months.
- Management stated that existing cash, cash equivalents, and investments are expected to fund operations into the first quarter of 2024, but not for the next 12 months from the financial statement issuance date. The filing therefore reports substantial doubt about the company’s ability to continue as a going concern.
Material changes versus 2021
- Net loss increased 39% and total operating expenses increased 46%, primarily due to expanded clinical, preclinical, employee, professional, and pre-commercialization activities.
- Research and development spending increased mainly because of COVAXIN clinical activities, OCU200 and OCU410/OCU410ST preclinical work, increased headcount, and the $1.0 million Washington University license issuance fee.
- General and administrative expense increased due to personnel and stock-based compensation, professional services, new headquarters costs, and pre-commercialization activities.
- Investing cash use increased to $17.0 million, including $13.3 million of marketable securities purchases and $4.5 million of property and equipment purchases.
- Common shares outstanding increased to approximately 221.6 million at year-end from 199.4 million, reflecting equity financings and equity compensation.
- In September 2022, Ocugen licensed inhaled mucosal COVID-19 vaccine rights from Washington University. The territory was expanded in January 2023 to include South Korea, Australia, and China.
- In November 2022, the CanSinoBIO collaboration was amended to include OCU410 and OCU410ST.
Pipeline, guidance, outlook, and management commentary
- OCU400 remained in a Phase 1/2 trial. Dose escalation in 10 RP subjects was completed, and additional RP and LCA enrollment at the maximum tolerated dose was continuing. Management intended to start a pediatric Phase 1/2 trial in the second quarter of 2023 and a Phase 3 trial near year-end 2023, subject to FDA discussions.
- Management intended to submit IND applications for OCU410 and OCU410ST in the second quarter of 2023.
- NeoCart received FDA RMAT designation, and FDA concurred with the confirmatory Phase 3 design. The company intended to begin the trial in the first half of 2024, subject to further FDA discussions. The prior NeoCart Phase 3 trial narrowly missed its primary endpoint.
- COVAXIN’s U.S. Phase 2/3 immuno-bridging and broadening trial met both co-primary immunogenicity endpoints, based on top-line results announced in January 2023. The company still expected to conduct an adult safety trial and obtain government funding to support a U.S. BLA pathway.
- Ocugen withdrew its Canadian COVAXIN NDS in August 2022 and was evaluating requirements for a resubmission. Mexico’s adult EUA remained active, but the company had not sold or administered doses under that authorization as of the filing.
- OCU200 clinical materials were produced, and an IND was submitted to the FDA in February 2023 for a Phase 1 DME trial.
- Management expected 2023 research and development and general and administrative expenses to increase and stated that significant additional capital would be required. Potential funding sources include equity or debt offerings, collaborations, licensing, grants, and government funding.
Principal risks, contingencies, and unusual items
- Going concern and dilution: The company has recurring losses, negative operating cash flow, no product revenue, and expects to require substantial additional financing. Future equity financing could dilute existing shareholders.
- Clinical and regulatory risk: All major programs remain dependent on successful clinical trials, manufacturing validation, and regulatory approval. Product candidates may be delayed, rejected, or fail to achieve commercial acceptance.
- COVAXIN risk: A U.S. BLA would require additional safety data and FDA discussions. Bharat Biotech has been addressing GMP deficiencies identified by the WHO, and the company remains dependent on third parties for supply and technology transfer.
- Manufacturing risk: Ocugen relies on CanSinoBIO, Bharat Biotech, Jubilant HollisterStier, and other third parties. Delays, quality problems, supply shortages, or regulatory findings could impair development and commercialization.
- Legal contingencies: Consolidated securities class actions and related derivative lawsuits remain pending. The motion to dismiss the securities class action had not been decided as of the filing date. No loss was accrued because a probable and reasonably estimable loss had not been identified.
- Licensing obligations: Material agreements include milestone payments, annual fees, royalties, and termination provisions. The Washington University agreement includes up to $37.0 million of development and commercial milestones; the SERI agreement includes $16.1 million of development and commercial milestones.
- Unusual items: Other income included approximately $1.4 million of interest income and $0.8 million collected on a previously impaired note receivable. The company also recorded $10.5 million of stock-based compensation.
- Subsequent financing: After year-end, Ocugen sold 4.5 million shares under its at-the-market program for net proceeds of $5.6 million. The company terminated that sales agreement effective February 27, 2023.
Most important facts for investors to verify
- Whether Ocugen can raise sufficient capital before its projected first-quarter 2024 funding horizon and on acceptable terms.
- The complete cash burn rate, expected 2023 spending, and any changes to management’s liquidity assumptions.
- FDA feedback, trial initiation, enrollment, and data milestones for OCU400, NeoCart, COVAXIN, and OCU200.
- The status and funding of the additional COVAXIN adult safety trial and the prospects for a U.S. BLA submission.
- The outcome of the securities class action and related derivative litigation.
- Progress and cost of the NeoCart manufacturing facility and the confirmatory Phase 3 trial.
- Manufacturing readiness, GMP remediation, technology transfer, and supply reliability for COVAXIN and other candidates.
- The effect of additional share issuance, stock-based compensation, warrants, and the Series B preferred stock on future dilution.
- Whether licensed intellectual property remains in good standing and whether milestone, royalty, and minimum payment obligations can be met.